Literature DB >> 15832463

Impact of empiric antibiotics and chest radiograph on delays in the diagnosis of tuberculosis.

J E Golub1, S Bur, W A Cronin, S Gange, T R Sterling, B Oden, N Baruch, G W Comstock, R E Chaisson.   

Abstract

SETTING: Maryland Department of Health and Mental Hygiene, Division of Tuberculosis (TB) Control.
OBJECTIVES: To assess the implications of antibiotic treatment of presumed community-acquired pneumonia (CAP) on delays in the diagnosis of TB, and to assess the frequency with which chest radiographs (CXRs) were utilized before a diagnosis of pneumonia or pulmonary TB was made.
DESIGN: A nested case-control study within a prospective study conducted to assess factors associated with delays in the diagnosis of TB.
RESULTS: Cases (n = 85; 54%) were patients who received antibiotics for non-TB diagnoses/indications prior to TB diagnosis, and controls (n = 73; 46%) were patients who had initially received TB therapy. Median health care delay for cases was 39 days vs. 15 days (P < 0.01) for controls. Median antibiotic delay was similar among all antibiotic classes. Of 54 patients who did not have a CXR at their first health care visit, 41 (79%) received empiric antibiotics, compared to 44/105 (42%) who had a CXR (P < 0.01). Only 31/54 (57%) patients initially diagnosed with CAP had a CXR at the time of diagnosis.
CONCLUSION: More widespread use of CXR when diagnosing CAP should reduce delays in diagnosing TB, and the unnecessary use of antibiotics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15832463

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  17 in total

Review 1.  Current prospects for the fluoroquinolones as first-line tuberculosis therapy.

Authors:  Howard Takiff; Elba Guerrero
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

2.  Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas.

Authors:  J-Y Wang; P-R Hsueh; I-S Jan; L-N Lee; Y-S Liaw; P-C Yang; K-T Luh
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

3.  Tuberculosis screening outcomes for newly diagnosed persons living with HIV, Nyanza Province, Kenya, 2009.

Authors:  B Burmen; S Modi; J S Cavanaugh; H Muttai; K D McCarthy; H Alexander; K Cain
Journal:  Int J Tuberc Lung Dis       Date:  2016-01       Impact factor: 2.373

4.  Prescribed and self-medication use increase delays in diagnosis of tuberculosis in the country of Georgia.

Authors:  A S Rabin; G Kuchukhidze; E Sanikidze; R R Kempker; H M Blumberg
Journal:  Int J Tuberc Lung Dis       Date:  2012-12-05       Impact factor: 2.373

5.  Impact of Fluoroquinolone Exposure Prior to Tuberculosis Diagnosis on Clinical Outcomes in Immunocompromised Patients.

Authors:  Ju Young Lee; Hyun Jung Lee; Yong Kyun Kim; Shinae Yu; Jiwon Jung; Yong Pil Chong; Sang-Oh Lee; Sang-Ho Choi; Tae Sun Shim; Yang Soo Kim; Jun Hee Woo; Sung-Han Kim
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

6.  Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death.

Authors:  Y F van der Heijden; F Maruri; A Blackman; E Holt; J V Warkentin; B E Shepherd; T R Sterling
Journal:  Int J Tuberc Lung Dis       Date:  2012-07-12       Impact factor: 2.373

7.  Patient and doctor delays in smear-negative and smear-positive pulmonary tuberculosis patients attending a referral hospital in Istanbul, Turkey.

Authors:  Gulbanu Horzum Ekinci; Esra Karakaya; Esra Akkutuk Ongel; Osman Haciomeroglu; Adnan Yilmaz
Journal:  ScientificWorldJournal       Date:  2014-10-14

8.  Delay in the diagnosis and treatment of pulmonary tuberculosis in Uzbekistan: a cross-sectional study.

Authors:  Tatiana V Belkina; Doniyor S Khojiev; Mirzagaleb N Tillyashaykhov; Zinaida N Tigay; Marat U Kudenov; Jurjen Duintjer Tebbens; Jiri Vlcek
Journal:  BMC Infect Dis       Date:  2014-11-25       Impact factor: 3.090

9.  Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia.

Authors:  Yu-Tzu Tseng; Yu-Chung Chuang; Chin-Chung Shu; Chien-Ching Hung; Chiung-Fang Hsu; Jann-Yuan Wang
Journal:  Crit Care       Date:  2012-10-25       Impact factor: 9.097

10.  Health system delay in pulmonary tuberculosis treatment in a country with an intermediate burden of tuberculosis: a cross-sectional study.

Authors:  Anamarija Jurcev-Savicevic; Rosanda Mulic; Karlo Kozul; Bozica Ban; Jasna Valic; Ljiljana Bacun-Ivcek; Ivan Gudelj; Gordana Popijac-Cesar; Snjezana Marinovic-Dunatov; Aleksandar Simunovic
Journal:  BMC Public Health       Date:  2013-03-21       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.